Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone. Thank you for standing by. Welcome to the Vistagen Therapeutics Fiscal Year 2026 Second Quarter Corporate Update Conference Call and Webcast. Please note that today's call is being recorded. At this time, I'd like to turn the call over to your host, Mark McPartland, Senior Vice President, Investor Relations at Vistagen. Mark. Thank you, Operator. Good afternoon, everyone, and welcome to our conference call and webcast. Earlier this afternoon, we filed our quarterly report on Form 10-Q and issued a press release for our fiscal year 2026 second quarter, which ended on September 30th, 2025, providing an overview on the progress in our Palisade III program for FASA-DNL and social anxiety disorder across our other clinical neuroscience programs. We encourage you to review the PR and 10-Q, which are available in the investor section of our website. Now, before we begin, please note that we will be making forelooking statements regarding our business during today's call based on our current expectations and information. These forelooking statements speak only as of today. Except, as law requires, we do not assume any duty to update any forelooking statements made today or in the future. Of course, forelooking statements of all risks and uncertainties and other actual results could differ materially from those anticipated by any forward-looking statements we make today. Additional information concerning risks and factors that could affect our business and financial results are included in the fiscal year 2026 second quarter form 10-Q for the period ending September 30th, 2025 and in future filings that we'll make with the SEC from time to time, all of which are available in the investor section of our website or of course on the SEC's website. Now with th...